Search research articles
Contact Us
Filters
Showing results (21-30 of 27) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 27 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2021
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
K N Moore, A M Oza, N Colombo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 5, 2023
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
E Pujade-Lauraine, F Selle, G Scambia, et al.
ESMO Open
|
January 25, 2023
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer
S Koppikar, A Oaknin, K Govind Babu, et al.
ESMO Open
|
June 10, 2025
Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer
S Nag, I Ray Coquard, S Gupta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 20, 2025
Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study
R S Kristeleit, S Ghamande, A Lisyanskaya, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 11, 2018
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
C Cruz, M Castroviejo-Bermejo, S Gutiérrez-Enríquez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 2, 2024
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
J A Ledermann, X Matias-Guiu, F Amant, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 27) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 27 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2021
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
K N Moore, A M Oza, N Colombo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 5, 2023
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
E Pujade-Lauraine, F Selle, G Scambia, et al.
ESMO Open
|
January 25, 2023
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer
S Koppikar, A Oaknin, K Govind Babu, et al.
ESMO Open
|
June 10, 2025
Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer
S Nag, I Ray Coquard, S Gupta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 20, 2025
Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study
R S Kristeleit, S Ghamande, A Lisyanskaya, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 11, 2018
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
C Cruz, M Castroviejo-Bermejo, S Gutiérrez-Enríquez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 2, 2024
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
J A Ledermann, X Matias-Guiu, F Amant, et al.
Page
of 3